Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.710
-0.890 (-34.23%)
At close: Sep 3, 2026, 4:00 PM EDT
1.698
-0.012 (-0.68%)
Pre-market: Sep 4, 2026, 5:52 AM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 33 employees as of December 31, 2025. The number of employees decreased by 4 or -10.81% compared to the previous year.
Employees
33
Change (1Y)
-4
Growth (1Y)
-10.81%
Revenue / Employee
n/a
Profits / Employee
-$803,182
Market Cap
3.08M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33 | -4 | -10.81% |
| Dec 31, 2024 | 37 | -3 | -7.50% |
| Dec 31, 2023 | 40 | -5 | -11.11% |
| Dec 31, 2022 | 45 | -9 | -16.67% |
| Dec 31, 2021 | 54 | -4 | -6.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 47 |
| Calidi Biotherapeutics | 29 |
| Curis | 24 |
| GeoVax Labs | 19 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Artelo Biosciences | 7 |
| SciSparc | 3 |
APVO News
- 18 hours ago - Aptevo AML data ‘highly encouraging,’ says Roth Capital - TheFly
- 22 hours ago - Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia - TheFly
- 22 hours ago - Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - Accesswire
- 13 days ago - Aptevo Therapeutics files to sell 6.44M shares of common stock for holders - TheFly
- 18 days ago - Aptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds - TheFly
- 18 days ago - Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30 - TheFly
- 20 days ago - Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - Accesswire
- 21 days ago - Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - Accesswire